Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Dr. Dan Streja MD

Clinical Professor of Medicine, UNIVERSITY OF CALIFORNIA, LOS ANGELES

What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Member of the Healthcare Council

Council Member Biography

Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA Medical Center of West Los Angeles. Dr. Streja has expertise in the management of diabetes, hypertension, hyperlipidemia, and antithrombotic therapy. He is a consultant in Endocrinology for a large managed care medical group. Dr. Streja also serves as the Medical Director of Infosphere Clinical Research. Previously, he was a Professor of Physiology at the University of Manitoba and specialized in the biochemistry of lipids and carbohydrate metabolism. Dr. Streja is a consultant for Abbott, BMS, Bayer, Eli-Lilly, Merck, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Pfizer, Roche, and Sankyo. (This is me - Update Profile)


Employment History

1979 - Unspecified
Consultant Endocrinologist, AFFILIATES IN MEDICAL SPECIALTIES MEDICAL GROUP, INC
1979 - Unspecified
Clinical Professor of Medicine, UNIVERSITY OF CALIFORNIA, LOS ANGELES
1979 - Unspecified
Co-director, UNITED STATES DEPT OF VETERANS AFFAIRS - CC

GLG NewsSM Analyses by Dan Streja(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Outsourcing of compassionate use of drugs?

January 18, 2008

No right to experimental drugs for dying patients: Supreme Court | news.yahoo.com

The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal illness have traveled outside the US to purchase hope when our management was offering none. Although in the majority of cases the hope was unjustified, the current decision will encourage healthcare providers residing outside the US to advertise for their services through the internet. The issue should be addressed by the legislators sooner rather than later. Drugs who improve quality of life, awaiting approval for survival indication or drugs looking promising in early clinical trials could be made available to dying patients with informed consent addressing our limitations.  

Leading institutions connect with Dan Streja through GLG

GLG Live Meetings with Dan Streja(?)

Dan Streja has not participated in any GLG Live Meetings.

View all GLG Live Meetings in Healthcare